Our mission and strategy
Our mission is to help people do more, feel better, live longer.
Our new business priorities
At an investor event on 26 July, we set out our new business priorities - centred around Innovation, Performance and Trust - which we will implement from 2018 onwards.
Read our new business priorities
Our current strategic priorities
The business is focused around the delivery of our strategic priorities which aim to increase growth, reduce risk and improve our long-term financial performance. These priorities are: grow a balanced global business, deliver more products of value, simplify the operating model and be a responsible business.
Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
Grow a balanced business
We have been creating a more balanced business and product portfolio, capable of delivering sustainable sales and earnings growth and improved returns to shareholders.
This is centred on our three business areas of Pharmaceuticals, Vaccines and Consumer Healthcare.
Group turnover outside USA and Europe
We invested £3.6 billion in 2016 in our search to develop new medicines, vaccines and consumer products.
Deliver more products of value
We have changed our R&D organisation so that it is better able to sustain a pipeline of products that offer valuable improvements in treatment for patients and healthcare providers.
This is underpinned by a focus on improving productivity and rates of return in R&D.
assets with data expected by 2018.
candidate vaccines in early, mid and late stage development
Our range of partners includes academic institutions, public-private partnerships, pharmaceutical and biotechnology companies
Simplify the operating model
As our business continues to change shape, we are transforming how we operate so that we can reduce complexity and become more efficient.
This frees up resources to reinvest elsewhere in the business, or return to shareholders wherever we see the most attractive returns.
Being a responsible business is central to our strategy, and how we deliver success is just as important as what we achieve. Ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
markets operating our new commercial model
in the Access to Medicine Index since launch in 2008
in the Pharmaceutical sector Dow Jones Sustainability Index score for economic, environmental and social performance
Find out more about us
What we do
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
Our Pharmaceuticals business discovers, develops and makes medicines to treat a broad range of the world's most common acute and chronic diseases.
Our Vaccines business has the broadest portfolio of any company, with vaccines for people of all ages. We deliver over two million vaccine doses per day to people across over 160 countries.
Our Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health. It has a portfolio of some of the world’s most trusted and best selling brands which includes Sensodyne, Voltaren, Horlicks and Panadol.